Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chroni...
Q1 2026
May 7, 2026
FY 2025
Mar 3, 2026
Q4 2025
Q3 2025
Nov 7, 2025
Q2 2025
Aug 7, 2025